LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED “TREAT AND EXTEND” DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Retina

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/IAE.0b013e3181d50cbfPMID 20517175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DOSING REGIMEN AND THE FREQUENCY OF MACULAR HEMORRHAGES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB

  2010cited by this paper
• Hemorrhagic recurrence of neovascular age-related macular degeneration not predicted by spectral domain optical coherence tomography.

  2010cited by this paper
• MACULAR HEMORRHAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER STABILIZATION WITH ANTIANGIOGENIC THERAPY

  2009cited by this paper
• “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION

  2009cited by this paper
• A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

  2009influential reference
• Photodynamic therapy for chronic central serous chorioretinopathy

  2009cited by this paper
• Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

  2008cited by this paper
• Acute Visual Loss and Chorioretinal Infarction after Photodynamic Therapy Combined with Intravitreal Triamcinolone

  2008cited by this paper
• Profound choroidal hypoperfusion after combined photodynamic therapy and intravitreal triamcinolone acetonide.

  2008cited by this paper
• An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

  2007cited by this paper
• Effect of Photodynamic Therapy (PDT) and Ranibizumab on Vascular Anatomy and Retinal Function in Neovascular Age-Related Macular Degeneration

  2007cited by this paper
• Ranibizumab according to need: a treatment for age-related macular degeneration.

  2007cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• SELF-REPORTED ACUTE DECREASE IN VISUAL ACUITY AFTER PHOTODYNAMIC THERAPY FOR AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• Choroidal neovascularization.

  2004cited by this paper
• Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6.

  2004cited by this paper
• Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy

  2004cited by this paper
• Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

  2003cited by this paper
• Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

  2003cited by this paper
• Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

  2002cited by this paper
• Treatment of age-related macular degeneration.

  2000cited by this paper
• Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group.

  1996cited by this paper

• Human expert grading versus automated quantification of fluid volumes in nAMD, DME and BRVO

  2025cites this paper
• Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration.

  2024cites this paper
• Publication trends of vascular endothelial growth factor (VEGF) and anti-VEGF treatment in neovascular age-related macular degeneration during 2001–2020: a 20-year bibliometric study

  2024cites this paper
• Early detection of fellow eye involvement in exudative AMD using OdySight: A remote-monitoring mobile medical application.

  2024cites this paper
• Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis

  2023influential citation
• Optimal Patient Adherence and Long-Term Treatment Outcomes of Neovascular Age-Related Macular Degeneration in Real-Life

  2022cites this paper
• Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration

  2022cites this paper
• The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test-case

  2022cites this paper
• To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study

  2022cites this paper
• Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration

  2022cites this paper
• Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions

  2021cites this paper
• Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration

  2021cites this paper
• Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy

  2021cites this paper
• OPTH_A_334641 4405..4418

  2021cites this paper
• Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy

  2021cites this paper
• SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION

  2021cites this paper
• Real-World Treatment Patterns in a Population With Neovascular AMD Treated With Anti-VEGF Agents.

  2021cites this paper
• Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

  2020cites this paper
• Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic

  2020cites this paper
• Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors

  2020cites this paper
• Multimodal imaging features and clinical relevance of subretinal lipid globules.

  2020cites this paper
• Progression of geographic atrophy with subsequent exudative neovascular disease in age-related macular degeneration: AREDS2 Report 24.

  2020cites this paper
• Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration

  2020cites this paper
• The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration

  2020cites this paper
• The Timing of Large Submacular Hemorrhage Secondary to Age-related Macular Degeneration Relative to Anti-VEGF Therapy.

  2020cites this paper
• Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems

  2020cites this paper
• Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.

  2019cites this paper
• Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration

  2019influential citation
• Impact of Drusen Burden on Incidence of Subclinical CNV With OCTA.

  2019cites this paper
• Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations

  2019cites this paper
• Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients

  2019cites this paper
• Comparison of outcomes between intravitreal ranibizumab and intravitreal aflibercept for diabetic macular edema with “Treat-and-Extend” regimen

  2019cites this paper
• Age‐related macular degeneration: using morphological predictors to modify current treatment protocols

  2018cites this paper
• Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

  2018cites this paper
• Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography.

  2018cites this paper
• RECURRENCE IN PATIENTS WITH TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION) AFTER INTRAVITREAL RANIBIZUMAB

  2017cites this paper
• Estrategia «Tratar y Extender» con aflibercept: efecto en diferentes tipos de neovascularización coroidea asociada a la edad

  2017cites this paper
• Retina Spatial Correspondence Between Intraretinal Fluid , Subretinal Fluid , and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration

  2017cites this paper
• Recent developments in age-related macular degeneration: a review

  2017cites this paper
• One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study

  2017cites this paper
• Treat-and-Extend Regimen for Macular Edema Secondary to Central Retinal Vein Occlusion: 12-Month Results.

  2017cites this paper
• Recent developments in age-related macular degeneration: a review

  2017cites this paper
• Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration.

  2017cites this paper
• Treat-and-extend approach with aflibercept: Effects on different subtypes of age-related choroidal neovascularisation.

  2017cites this paper
• Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

  2017cites this paper
• Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration

  2017cites this paper
• Recent developments in age-related macular degeneration: a review

  2017cites this paper
• Differential diagnosis of neovascular age-related macular degeneration

  2017cites this paper
• Functional impact of treatment with ranibizumab under a reactive strategy in patients with neovascular age-related macular degeneration

  2017cites this paper
• Functional impact of treatment with ranibizumab under a reactive strategy in patients with neovascular age-related macular degeneration.

  2017cites this paper
• A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

  2017cites this paper
• Correspondence to: Morphological features in eyes with endophthalmitis after cataract surgery – histopathology and optical coherence tomography assessment by Yolcy et al.

  2017cites this paper
• Growth of Type 1 Neovascularization Following Cessation of Anti-Vascular Endothelial Growth Factor Therapy as a Possible Explanation for Treatment Resistance

  2017cites this paper
• Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age‐related macular degeneration: a comparative 12 Month study

  2017cites this paper
• Diagnosing Choroidal Neovascularization in Asymptomatic Individuals Using Optical Coherence Tomography Angiography.

  2017cites this paper
• Impacto funcional del tratamiento con ranibizumab bajo una estrategia reactiva en pacientes con degeneración macular asociada a la edad exudativa neovascular

  2017cites this paper
• Self‐recognition of recurrences among patients with exudative age‐related macular degeneration

  2016cites this paper
• Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials.

  2016cites this paper
• TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

  2016cites this paper
• Improving accessibility to intravitreal anti-vascular endothelial growth factor treatment for ophthalmic patients in a peripheral centre.

  2016cites this paper
• Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.

  2016cites this paper
• Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.

  2016cites this paper
• Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration

  2016cites this paper
• METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2016cites this paper
• One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation

  2016cites this paper
• TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN

  2016cites this paper
• Umstellung des Therapieschemas pro re nata (PRN) auf Treat and Extend (T&E) in der intravitrealen Therapie mit Anti-VEGF-Medikamenten in der Praxis oder kleineren Institutionen

  2016influential citation
• Thinking Beyond Wet Age-Related Macular Degeneration

  2015cites this paper
• Anti-VEGF Therapy and the Retina: An Update

  2015cites this paper
• Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections

  2015cites this paper
• Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

  2015cites this paper
• Anti-vascular endothelial growth factor indications in ocular disease.

  2015cites this paper
• Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration

  2015cites this paper
• Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.

  2015cites this paper
• Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration

  2015cites this paper
• Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration

  2015cites this paper
• DETECTION OF NONEXUDATIVE CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY

  2015cites this paper
• GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2015cites this paper
• TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations

  2015cites this paper
• Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?

  2015cites this paper
• Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy.

  2015cites this paper
• [Management of aflibercept in routine clinical practice].

  2015cites this paper
• Age-related Macular Deg neration Ranibizumab in Treatment for Age-related Macular Degeneration

  2014cites this paper
• Treat and Extend Versus Treat and Observe Regimens in Wet Age- related Macular Degeneration Patients Treated with Ranibizumab: 3-year Surveillance Period

  2014cites this paper
• Radial versus raster spectral-domain optical coherence tomography scan patterns for detection of macular pathology.

  2014cites this paper
• Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life

  2014cites this paper
• Pharmacotherapy for neovascular age-related macular degeneration

  2014cites this paper
• Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

  2014cites this paper
• Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen

  2014cites this paper
• Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration

  2014cites this paper
• Facultad de Medicina Departamento de Medicina

  2014cites this paper
• Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results

  2014cites this paper
• Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients

  2014cites this paper
• Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

  2014cites this paper
• Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010

  2013cites this paper
• Anti-VEGF Therapy for AMD: Results and Guidelines

  2013cites this paper
• Resultados a largo plazo del tratamiento de la DMAE húmeda con Ranibizumab en la práctica clínica diaria

  2013cites this paper
• Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

  2013cites this paper
• Growth of type 1 neovascularization following cessation of anti-vascular endothelial growth factor therapy as a possible explanation for treatment resistance.

  2013cites this paper
• A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION

  2013cites this paper